Literature DB >> 3229872

Effect of benazepril, a converting enzyme inhibitor, on plasma levels and activity of acenocoumarol and warfarin.

A Van Hecken1, I De Lepeleire, R Verbesselt, J Arnout, J Angehrn, C Youngberg, P J De Schepper.   

Abstract

The effect of benazepril (CGS 14824), 20 mg/day orally, on the steady-state pharmaco-dynamics and plasma levels of the anticoagulants, warfarin and acenocoumarol, was studied in healthy volunteers. The anticoagulant activity of acenocoumarol was not affected by benazepril; there was an apparent slight but statistically significant reduction of the anticoagulant effect of warfarin. The magnitude of the inhibitory effect was considered not to be clinically important. There was no effect of benazepril on plasma steady-state levels of either anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3229872

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  3 in total

Review 1.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.

Authors:  A Van Hecken; R Verbesselt; M Depré; T B Tjandramaga; J Angehrn; W Cawello; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.